Compare
Evolus, Inc. vs Ironwood Pharmaceuticals Inc vs Xeris Biopharma Holdings, Inc. vs CorMedix Inc.
| Latest fiscal year | Evolus, Inc. EOLS | Ironwood Pharmaceuticals Inc IRWD | Xeris Biopharma Holdings, Inc. XERS | CorMedix Inc. CRMD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $297.18M | $296.15M | $291.85M | $311.71M |
| Revenue growth (YoY) | +11.6% | -15.7% | +43.7% | +617.0% |
| Gross margin | 66.3% | n/a | n/a | 88.5% |
| Operating margin | -11.0% | 33.3% | 8.5% | 48.2% |
| Net margin | -17.4% | 8.1% | 0.2% | 52.3% |
| Net income | -$51.64M | $24.02M | $554.0K | $163.06M |
| EPS (Diluted) | -$0.80 | $0.15 | $0.00 | $2.04 |
| Operating cash flow | -$42.27M | $127.04M | $28.63M | $175.05M |
| Free cash flow | -$45.71M | $127.01M | n/a | $172.79M |
| Cash & equivalents | $53.83M | $215.46M | $111.04M | $144.84M |
| Total assets | $225.87M | $396.90M | $383.53M | $826.14M |
| Total liabilities | $248.97M | n/a | $369.84M | $420.83M |
| Shareholders' equity | -$23.11M | -$261.83M | $13.69M | $405.31M |
| Return on year-end equity | n/a | n/a | 4.0% | 40.2% |
| Shares outstanding | 65.01M | 163.06M | 166.22M | 79.26M |
Revenue, most recent five fiscal years
| Fiscal year | Evolus, Inc. | Ironwood Pharmaceuticals Inc | Xeris Biopharma Holdings, Inc. | CorMedix Inc. |
|---|---|---|---|---|
| Latest | $297.18M Ended 2025-12-31 | $296.15M Ended 2025-12-31 | $291.85M Ended 2025-12-31 | $311.71M Ended 2025-12-31 |
| 1 year earlier | $266.27M Ended 2024-12-31 | $351.41M Ended 2024-12-31 | $203.07M Ended 2024-12-31 | $43.47M Ended 2024-12-31 |
| 2 years earlier | $202.09M Ended 2023-12-31 | $442.74M Ended 2023-12-31 | $163.91M Ended 2023-12-31 | n/a |
| 3 years earlier | $148.62M Ended 2022-12-31 | $410.60M Ended 2022-12-31 | $110.25M Ended 2022-12-31 | $65.4K Ended 2022-12-31 |
| 4 years earlier | $99.67M Ended 2021-12-31 | $413.75M Ended 2021-12-31 | $49.59M Ended 2021-12-31 | $190.9K Ended 2021-12-31 |